
zzso is a zzso zzso isolated from the marine zzso zzso zzso 

This phase I study of zzso given as a zzso zzso infusion daily for 5 days every 3 weeks was conducted in patients with zzso solid zzso zzso were to define the dose limiting zzso the zzso tolerated dose, and the recommended phase II zzso 

zzso patients were accrued on zzso zzso ranged from 80 zzso to 1500 zzso Eleven patients received more than three cycles of zzso zzso zzso occurred at 1500 zzso and zzso zzso and consisted of zzso zzso zzso fatigue, skin rash and zzso zzso to moderate muscular pain and weakness was noted in patients treated with multiple cycles with no significant drug related zzso Bone zzso toxicity was not zzso The recommended dose for phase II studies was 1200 zzso daily for 5 days, every 3 zzso zzso studies performed during the first cycle demonstrated that therapeutic plasma levels of zzso are reachable well below the recommended zzso Nine patients with progressive disease at study entry had stable disease and two had minor responses, one in zzso cell lung cancer and one in zzso zzso 

zzso given at a dose of 1200 zzso daily for 5 days, every 3 weeks is well tolerated with few severe adverse zzso This schedule of zzso is under evaluation in phase II studies in zzso zzso and solid zzso 

